Volume 133, Issue 7



February 14, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Review Series: Advances in Multiple Myeloma. See the articles in the series.

Megakaryocytes and platelets from a novel human adipose tissue–derived mesenchymal stem cell line
In a plenary paper, the investigators report the production of platelets from human adipose tissue–derived mesenchymal stem/stromal cells for use in transfusion medicine as a donor-independent source.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
This paper presents the outcomes for all isocitrate dehydrogenase 2 (IDH2)–mutant patients with relapsed or refractory acute myeloid leukemia treated with the targeted drug enasidenib in this first-in-human phase 1/2 study. It reports data on molecular clearance and molecular relationships to response or resistance.

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
These investigations of carfilzomib-induced cardiotoxicity in an animal model reveal that the causative molecular mechanisms are related not to the inhibition of the proteasome function but rather to autophagy pathway modulation, inactivation of AMPKα, and upregulation of protein phosphatase 2A activity.

Low-dose chidamide restores immune tolerance in ITP in mice and humans
The investigators explore the role of low doses of the histone deacetylase inhibitor chidamide in restoring immune tolerance in immune thrombocytopenia (ITP) as a novel approach for the treatment of ITP.

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
The authors describe a novel strategy for mitigating chimeric antigen receptor (CAR) T cell–associated cytokine release syndrome and neurotoxicity.

Introduction to a review series on advancse in multiple myeloma
This series of reviews on advances in multiple myeloma, written by experts in the field, deals with clinically timely questions. What is the optimal imaging approach at diagnosis and follow-up? Is frontline high-dose melphalan with stem cell support still the standard of care? With so many novel drugs, are we ready for patient-adjusted treatment?

The articles in this review series include the following:

An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1
These studies provide insight into the source of intravascular tissue-type plasminogen activator (tPA) and establish an important role for hepatocytes in regulating the basal level of plasma tPA.

Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence
This paper demonstrates a critical role for the transforming growth factor β receptor endoglin in self-renewal of mouse bone marrow hematopoietic stem cells.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.